AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 SEP 10 - (NewsRx.com & NewsRx.net) -- A combination of the gp120 Thai E and SF2 vaccines elicited a strong immune response in healthy Thai adults and should be considered for phase 3 clinical testing.
According to recent research from an international group of scientists, "Safety and immunogenicity of two recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein (gp) 120 vaccines derived from SF2 (subtype B) and CM235 (CRF01_AE, Thai E) were evaluated in 370 Thai adults at low risk of HIV infection."
"Various doses of CM235 (25, 50, or 100 microgram) and SF2 (0, 25, or 50 microgram) gp120 were used," said Punnee Pitisuttithum at Mahidol University in Thailand and fellow members of the Thai AIDS Vaccine Evaluation Group. "Eighty volunteers received placebo. There were no serious adverse events related to vaccination. Binding antibody developed in all vaccine recipients. There was no dose response to CM235 gp120, but a dose response to gp120 SF2 was present. Neutralizing antibodies to subtype E HIV-1 NPO3 and subtype B HIV-1 SF2 developed in 84% and 82% of vaccine recipients, respectively. Lymphoproliferative responses were detected in >95% of vaccine ...
Source: HighBeam Research, gp120 Thai E and SF2 vaccines elicits immune response in healthy Thai...